Ono Pharmaceutical Co Ltd

Ono Pharmaceutical maintains a strong liquidity position with a current ratio of 3.07 and a cash and equivalents balance of ¥204.57 billion, which exceeds its long-term debt of ¥146.68 billion. The company's debt-to-equity ratio of 0.19 indicates a conservative capital structure, with total liabilities of ¥281.59 billion compared to total equity of ¥782.45 billion. Free cash flow of ¥31.55 billion supports operational flexibility and potential for shareholder returns. The company's profitability metrics show a return on equity (ROE) of 6.4% and a return on assets (ROA) of 4.7%, which are in line with industry norms for pharmaceutical firms. Operating income of ¥59.80 billion and net income of ¥50.05 billion reflect a healthy gross margin of 69.6%, derived from revenue of ¥486.87 billion. These figures suggest a stable and efficient business model. Geographically, Ono Pharmaceutical's revenue is primarily concentrated in Japan, with limited international exposure disclosed in the available data. The company operates in a single business segment focused on pharmaceuticals, with no material diversification into other therapeutic areas or product lines. Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or contraction expected in the next fiscal year. Capital expenditures of -¥7.99 billion suggest a reduction in investment activity, which may indicate a focus on cost optimization or a shift in strategic priorities. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's conservative debt levels and strong cash position reduce the likelihood of near-term financial distress. However, the absence of strong buy recommendations from analysts (mean recommendation of 3.14) suggests a cautious outlook among market participants. Recent investor relations data shows a mean price target of ¥2,222.73 and a median price target of ¥2,200.00, with a wide range from ¥1,750.00 to ¥2,950.00. The lack of strong buy ratings (0) and the high number of hold ratings (10) indicate a generally neutral sentiment among analysts, with limited upside potential in the near term.